HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Omenn, G. S. Search for Related Content PubMed PubMed Citation Articles by Omenn, G. S.

Human Lung Cancer Chemoprevention Strategies^*

Parker B. Francis Lecture

^* From the University of Michigan, Ann Arbor, MI.

Correspondence to: Gilbert S. Omenn, MD, PhD, Professor of Internal Medicine, Human Genetics, and Public Health, A510C MSRB I, University of Michigan, Ann Arbor, MI, 48109-0656; e-mail: gomenn{at}umich.edu

Pharmacologic or nutritional prevention of lung cancers is needed, especially for 60 million Americans who are former smokers. A portfolio of large-scale trials of beta-carotene, beta-carotene with and without vitamin E, and beta-carotene plus vitamin A demonstrated no benefit whatsoever from beta-carotene. The -Tocopherol/ß-Carotene Trial and the ß-Carotene and Retinol Efficacy Trial found significant increases in lung cancer risk and total mortality. Laboratory research soon identified multiple adverse molecular effects. Nevertheless, chemoprevention remains an active, promising strategy, with new hypotheses and new candidate agents, including many already approved as therapies. The most active area currently is focused on selective inhibition of arachidonic metabolism, both Cox-2 and Lox pathways.

Key Words: arachidonic acid pathways • beta-carotene • chemoprevention • lung cancer